After raising questions surrounding dosing levels, the FDA has freed Amylyx’s early-stage amyotrophic lateral sclerosis (ALS) candidate from a clinical…
Researchers at the Autism Research Centre at Cambridge University have uncovered significant disparities in healthcare experiences among autistic individuals who…